Your browser doesn't support javascript.
loading
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).
Ma, B B Y; Goh, B C; Lim, W T; Hui, E P; Tan, E H; Lopes, G de Lima; Lo, K W; Li, L; Loong, H; Foster, N R; Erlichman, C; King, A D; Kam, M K M; Leung, S F; Chan, K C; Chan, A T C.
Affiliation
  • Ma BB; State Key Laboratory of Oncology in South China, Sir Y.K. Pao Centre for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong SAR, brigette@clo.cuhk.edu.hk.
Invest New Drugs ; 33(4): 985-91, 2015 Aug.
Article in En | MEDLINE | ID: mdl-26084990

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nasopharyngeal Neoplasms / Protein Kinase Inhibitors / Heterocyclic Compounds, 3-Ring / Neoplasm Recurrence, Local / Antineoplastic Agents Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2015 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nasopharyngeal Neoplasms / Protein Kinase Inhibitors / Heterocyclic Compounds, 3-Ring / Neoplasm Recurrence, Local / Antineoplastic Agents Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2015 Type: Article